RecruitingPhase 3NCT06091748
Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors
An Open-label, Single Arm Clinical Trial of Gallium (68Ga) Edotreotide PET-CT Scan for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Enrollment
66 participants
Start Date
Feb 22, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
This is a single-arm imaging study using DOTATOC peptide, labelled with the Gallium (68Ga) tracer.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria4
- Able and willing to provide a written informed consent;
- \~75 years old,male or female；
- ECOG performance status 0 or 1;
- Confirmed or suspicion of GEP-NET.
Exclusion Criteria3
- Unable to lie flat for the entire imaging duration (e.g. persistent cough, claustrophobia, severe arthritis, etc.), unable to enter the PET/CT device;
- Individuals planning to be pregnant, and lactating women;
- Individuals with concurrent active infections or with unexplained fever \>38.5°C for more than 1 hour during the screening period or prior to administration of investigational medication.
Interventions
DRUG68Ga-DOTATOC
Detection of somatostatin positive lesions in GEP-NETs
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06091748